https://explicyte.com/case-study/ffpe-transcriptomics-visium-vs-xenium-vs-chromium/ 2026-10-28T12:57:31+00:00 https://explicyte.com/wp-content/uploads/2026/07/10x-Genomics-for-FFPE-Tumor-Analysis-Visium-vs-Chromium-vs-Xenium-2-1.jpg https://explicyte.com/wp-content/uploads/2025/11/FFPE-Tumor-specimen-10x-certified-service-provider-explicyte.jpg https://explicyte.com/wp-content/uploads/2025/11/chromium-10x-CRO-FFPE-tumor-sample-single-cell-RNA-seq.jpg https://explicyte.com/wp-content/uploads/2025/11/VIsium-HD-Service-Provider-10x-FFPE-tumor-specimen.jpg https://explicyte.com/wp-content/uploads/2025/11/Xenium-FFPE-sample-single-cell-spatial-analysis-CRO.jpg https://explicyte.com/wp-content/uploads/2025/11/Chromium-visium-xenium-transcriptomics-CRO.jpg https://explicyte.com/wp-content/uploads/2025/11/Single-cell-spatial-transcriptomics-data-analysis-service-provider-CRO-immuno-oncology.jpg https://explicyte.com/case-study/histology-services-ihc-ihf-150-validated-markers-120-panels-for-immuno-oncology/ 2026-10-28T12:56:45+00:00 https://explicyte.com/wp-content/uploads/2026/07/Histology-services-CRO-immuno-oncology-validated-markers-panels-IHC-IHF.jpg https://explicyte.com/case-study/stamp-xenium-for-cytokine-release-syndrome-analysis-in-pbmcs/ 2026-09-08T07:07:02+00:00 https://explicyte.com/wp-content/uploads/2026/06/Xenium-stamp-for-CRS-analysis.jpg https://explicyte.com/case-study/from-cell-phenotype-to-spatial-relationships-multiplex-digital-pathology-in-nsclc/ 2026-08-27T15:24:03+00:00 https://explicyte.com/wp-content/uploads/2026/08/automated-histopathology-services-immuno-oncoloy-CRO-services.jpg https://explicyte.com/wp-content/uploads/2026/08/digital-pathology-automated-histopathology-Detection-tumor-infiltrating-lymphocytes-1-1-1024x612.jpg https://explicyte.com/wp-content/uploads/2026/08/digital-pathology-CRO-services-immunofluorescence-biomarkers-parients-tumor-samples-biopsies-1024x430.jpg https://explicyte.com/wp-content/uploads/2026/08/digital-pathology-bioinformatic-spatial-analysis-cell-distance-CRO-immuno-oncology-services-1024x603.jpg https://explicyte.com/wp-content/uploads/2026/08/digital-pathology-bioinformatic-spatial-analysis-cell-distance-CRO-cancer-immunotherapy-services-600x433-1.jpg https://explicyte.com/case-study/sample-multiplexing-for-xenium-with-bioptimus/ 2026-07-29T10:54:23+00:00 https://explicyte.com/wp-content/uploads/2026/06/Sample-multiplexing-Xenium-Bioptimus.jpg https://explicyte.com/case-study/xenium-beyond-5k/ 2026-07-29T10:54:13+00:00 https://explicyte.com/wp-content/uploads/2026/06/Xenium-beyond-5K.jpg https://explicyte.com/case-study/data-science-services-analyzing-10x-genomics-datasets-in-4-weeks/ 2026-07-29T10:44:03+00:00 https://explicyte.com/wp-content/uploads/2026/07/Data-Science-Services-Analyzing-10x-Genomics-datasets-in-4-weeks.jpg https://explicyte.com/case-study/xenium-stamp-case-study-analysis-of-activated-pbmcs-nivolumab-with-the-xenium-io-panel-380-genes/ 2026-07-29T09:43:04+00:00 https://explicyte.com/wp-content/uploads/2025/09/Analysis-of-activated-PBMCs-nivolumab-with-the-Xenium-IO-panel.jpg https://explicyte.com/case-study/bite-tarlatamab-efficacy-crs-case-study/ 2026-07-29T08:39:52+00:00 https://explicyte.com/wp-content/uploads/2026/07/A-cell-based-system-to-assess-multi-specifics-in-relevant-target-expressing-cell-co-cultures.jpg https://explicyte.com/case-study/ovarian-cancer-ascites-as-a-translational-platform-to-investigate-tumor-progression-and-therapeutic-response/ 2026-07-28T16:02:34+00:00 https://explicyte.com/wp-content/uploads/2026/07/Ovarian-Cancer-Ascites-as-a-Translational-Platform-to-Investigate-Tumor-Progression-and-Therapeutic-Response.jpg https://explicyte.com/wp-content/uploads/2026/07/flow-cytometry-phenotyping-of-immune-cells-in-ovarian-ascites.png https://explicyte.com/wp-content/uploads/2026/07/immune-profiling-ascites.png https://explicyte.com/wp-content/uploads/2026/07/ascite-macrophrage-polarization.png https://explicyte.com/case-study/mixed-leukocyte-reaction-assay-to-assess-immunotherapeutic-activity/ 2026-07-28T14:16:56+00:00 https://explicyte.com/wp-content/uploads/2026/07/mixed-leukocyte-reaction-assay.jpg https://explicyte.com/wp-content/uploads/2026/07/16902.png https://explicyte.com/wp-content/uploads/2026/07/16982.png https://explicyte.com/case-study/evaluation-of-adcc-activity-using-primary-nk-cells-and-skov3-ovarian-tumor-cells/ 2026-07-09T15:20:18+00:00 https://explicyte.com/wp-content/uploads/2026/07/ADCC-assay-2.jpg https://explicyte.com/wp-content/uploads/2026/07/Evaluation-of-the-expression-of-CD16-and-CD56-in-primary-NK-cells-by-flow-cytometry-after-NK-isolation-from-PBMCs-and-following-24h-activation.png https://explicyte.com/wp-content/uploads/2026/07/Evaluation-of-the-expression-of-HER2-and-EGFR-antigens-in-SKOV3-tumor-cells-by-flow-cytometry.png https://explicyte.com/wp-content/uploads/2026/07/Combination-of-NK-cells-with-anti-HER2-or-anti-EGFR-antibodies-enhances-NK-mediated-cytotoxicity-in-SKOV3-ovarian-tumor-cells-in-a-NK-ratio-dependent-manner.png https://explicyte.com/wp-content/uploads/2026/07/Dose-dependent-anti-EGFR-antibody-Cetuximab-dependent-cell-cytotoxicity-in-SKOV3-ovarian-tumor-cells.png https://explicyte.com/case-study/adenosine-mediated-suppression-of-dendritic-cell-function/ 2026-07-09T15:18:44+00:00 https://explicyte.com/wp-content/uploads/2026/07/Adenosine-mediated-suppression-of-dendritic-cell-function.jpg https://explicyte.com/wp-content/uploads/2026/07/Phenotype-and-functional-activity-of-adenosine-differentiated-human-DCs-scaled.png https://explicyte.com/wp-content/uploads/2026/07/Adenosine-induces-phenotypically-aberrant-DC-population-scaled.png https://explicyte.com/case-study/geomx-dsp-analysis-of-tumor-and-stromal-compartments-in-pre-treatment-nsclc-samples/ 2026-07-09T15:17:47+00:00 https://explicyte.com/wp-content/uploads/2026/07/GeoMx-DSP-analysis-of-tumor-and-stromal-compartments-in-pre-treatment-NSCLC-samples.jpg https://explicyte.com/wp-content/uploads/2026/07/GeoMx-workflow-analysis.png https://explicyte.com/wp-content/uploads/2026/07/Analysis-of-the-determinants-of-the-ICI-response.png https://explicyte.com/case-study/quantitative-histology-to-characterize-immune-contexture-in-human-lung-adenocarcinoma-samples/ 2026-07-09T11:49:38+00:00 https://explicyte.com/wp-content/uploads/2026/07/Quantitative-histology-to-characterize-immune-contexture-in-human-lung-adenocarcinoma-samples.jpg https://explicyte.com/wp-content/uploads/2026/07/Multiplexed-immunohistochemistry-imaging-for-immune-contexture-analysis-in-human-lung-adenocarcinomas.png https://explicyte.com/case-study/multiparametric-cytokine-profiling-across-immune-cell-based-assay-platforms/ 2026-07-09T10:12:04+00:00 https://explicyte.com/wp-content/uploads/2026/07/cytokine-release-assay-CRO-immuno-oncology.jpg https://explicyte.com/wp-content/uploads/2020/04/PBMC-release-of-key-inflammatory-cytokines-is-induced-upon-CD3-activation-and-further-optimized-by-immune-checkpoint-inhibitors.png https://explicyte.com/wp-content/uploads/2020/04/T-cell-IFN%F0%9D%9C%B8-release-is-induced-in-a-MLR-assay-and-further-optimized-by-immune-checkpoint-inhibitors.png https://explicyte.com/wp-content/uploads/2020/04/IFN%F0%9D%9C%B8-release-by-activated-NK-cells-is-induced-against-tumor-cells-and-is-optimized-by-anti-tumor-antigen-antibodies.png https://explicyte.com/wp-content/uploads/2020/04/M2-macrophage-phenotype-and-its-mediated-T-cell-response-immunosuppression-are-reversed-by-molecular-pathway-modulators-and-immune-checkpoint-inhibitors.png https://explicyte.com/case-study/b-cells-and-tertiary-lymphoid-structures-as-key-players-in-anti-tumor-immune-response/ 2026-07-09T09:36:03+00:00 https://explicyte.com/wp-content/uploads/2026/07/Multiparametric-TLS-characterization-by-digital-pathology.jpg https://explicyte.com/wp-content/uploads/2026/07/immunohistofluorescence-imaging-of-TLS-in-a-sarcoma-patient-sample.png https://explicyte.com/wp-content/uploads/2026/07/Multiparametric-TLS-characterization-by-digital-pathology.png https://explicyte.com/case-study/functional-evaluation-of-neutrophil-migration-toward-tumor-associated-chemoattractants/ 2026-07-08T16:14:57+00:00 https://explicyte.com/wp-content/uploads/2026/07/chemotaxis-assay-neutrophils-cancer-immunotherapy-CRO-1536x864-1.jpg https://explicyte.com/wp-content/uploads/2026/07/Functional-evaluation-of-neutrophil-migration-toward-tumor-associated-chemoattractants.png https://explicyte.com/case-study/immune-cell-mediated-killing-of-h1299-lung-cancer-cells-in-the-presence-of-various-concentrations-of-acd3/ 2026-07-08T15:48:35+00:00 https://explicyte.com/wp-content/uploads/2026/07/In-Vitro-Immune-Cell-Mediated-Killing.jpg https://explicyte.com/wp-content/uploads/2026/07/Immune-cell-mediated-killing-of-H1299-lung-cancer-cells-in-the-presence-of-various-concentrations-of-aCD3.png https://explicyte.com/case-study/dc-mediated-killing-assay-cancer-vaccines-oncolytic-viruses-adjuvants/ 2026-07-07T17:19:35+00:00 https://explicyte.com/wp-content/uploads/2026/07/tumor-antigen-specific-killing-APC-DC-mediated-t-cell-assays.jpg https://explicyte.com/wp-content/uploads/2026/07/Exposure-of-DCs-to-a-target-tumor-antigen-peptide-enhances-their-antigenic-presentation-2.jpg https://explicyte.com/wp-content/uploads/2026/07/Target-TA-exposed-DCs-optimized-priming-CD8-T-cells-increased-IFNg-levels-released-in-CD8-T-cell-DC-co-cultures.jpg https://explicyte.com/wp-content/uploads/2026/07/Specific-TA-exposed-DC-mediated-priming-of-CD8-T-cells-results-in-the-induction-of-an-adaptive-effector-T-cell-mediated-killing-towards-SK-MEL-5-tumor-cells.jpg https://explicyte.com/wp-content/uploads/2025/01/Confirming-target-antigen-expression-in-FFPE-cohorts.jpg